136117-74-3

Usage

Uses

Used in Organic Synthesis:
Imidazo[1,2-a]pyridine-8-carboxaldehyde (9CI) is used as a key intermediate in organic synthesis for its ability to form a variety of complex molecules. Its presence in the synthesis process allows for the creation of compounds with diverse applications, including those in the pharmaceutical industry.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Imidazo[1,2-a]pyridine-8-carboxaldehyde (9CI) is utilized as a precursor in the development of new drugs. Its unique structure contributes to the design of molecules with potential therapeutic properties, making it an essential component in drug discovery and medicinal chemistry.
Used in the Development of Biologically Active Compounds:
Imidazo[1,2-a]pyridine-8-carboxaldehyde (9CI) is employed as a building block in the synthesis of biologically active compounds. Its incorporation into these compounds can lead to the discovery of new pharmaceutical agents with specific biological activities, contributing to advancements in medicine.
Used in the Creation of Pharmaceutical Drugs:
As a versatile compound, Imidazo[1,2-a]pyridine-8-carboxaldehyde (9CI) is used in the formulation of pharmaceutical drugs. Its reactivity and structural features enable the development of drugs with novel mechanisms of action, potentially leading to more effective treatments for various diseases and conditions.

InChI:InChI=1/C8H6N2O/c11-6-7-2-1-4-10-5-3-9-8(7)10/h1-6H

Upstream product

• 133427-07-3 methyl 8-imidazo<1,2-a>pyridinecarboxylate 
• 111477-17-9 8-hydroxymethylimidazo[1,2-a]pyridine 
• 158020-74-7 imidazo[1,2-a]pyridine-8-carboxylic acid ethyl ester 
• 13362-26-0 2-aminopyridine-3-carboxylic acid ethyl ester 
• 24517-64-4 2-amino-3-pyridinecarbonitrile 
• 14667-47-1 methyl 2-aminonicotinate 
• 136117-70-9 8-imidazo<1,2-a>pyridinecarbonitrile 

Downstream Products

• 1033434-54-6 3-bromoimidazo[1,2-a]pyridine-8-carbaldehyde 
• 1402911-24-3 trans-3-{[4-(1,1-dimethylethyl)-3,5-difluorophenyl]oxy}-N-(imidazol[1,2-a]pyridin-8-ylmethyl)cyclobutanamine 
• 1402911-34-5 trans-3-{[4-fluoro-3-(trifluoromethyl)phenyl]oxy}-N-(imidazo[1,2-a]pyridin-8-ylmethyl)cyclobutanamine, hydrochloride 
• 1402911-15-2 cis-3-[(2,3-dichlorophenyl)oxy]-N-(imidazo[1,2-a]pyridin-8-ylmethyl)cyclobutamine 
• 372147-63-2 (Z)-ethyl α-[(triphenylphosphoranylideneamino)-β-(imidazo[1,2-a]pyridin-8-yl)]propenoate 

Relevant academic research and scientific papers

SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

IMIDAZO [1, 2-A] PYRROLO [3, 2-C] PYRIDINE COMPOUNDS USEFUL AS PESTIVIRUS INHIBITORS

The present invention relates to a series of novel imidazo[1,2-α]pyrrolo[3,2-c]pyridines (or also named 6H-1,3a,6-Tri-aza-αy-indacenes) and derivatives thereof, according to formula: (I); The present invention also relates to processes for the preparation of imidazo[1,2-α]pyrrolo[3,2-c]pyridines, their use as. a, medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses belonging to the family of the Flaviviridae and more preferably infections with Bovine Viral Diarrhea virus (BVDV).

BENZISOXAZOLE COMPOUND

Disclosed is a compound represented by the general formula (I) or a salt thereof: wherein any one of R1, R2 and R3 represents a group represented by the formula: -(CH2)m-NR11R12 (wherein m is 1 or 2; and R11 and R12 independently represent a hydrogen atom or a C1-6 alkyl group or may, together with a nitrogen atom to which R11 and R12 are bound, form a 4- or 5-membered cyclic group); the remaining two or R1, R2 and R3 independently represent a group represented by the formula: -(O)n-R21 (wherein n is 0 or 1; and R21 represents a hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or the like); and R4 represents a C1-6 alkyl group which may have a substituent or the like.

Heterocyclization of functionalized vinylic derivatives of imidazo[1,2-α]pyridines

Heterocyclization of functionalized vinylic derivatives of imidazo[1,2-α]pyridines was explored experimentally and theoretically using semiempirical AM1 and ab initio methods. A range of functionalized vinylic derivatives (azido, amino, and carbodiimide groups) were prepared for conversion into pyrroloazaindoles 19-22, imidazo[1,x]-; (x=5, 6, 7, 8), [2,6]-, and [2,7]naphthyridines 28-30, 35-38 by thermal reaction. In the case of vinylic groups in the 5 position, peri annulation also was observed. The experimental and theoretical data are compared and discussed.

Imidazo[1,2-a]pyridines. Synthesis and inotropic activity of new 5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinone derivatives

A series of 1,2-dihydro-5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinones was synthesized and evaluated for positive inotropic activity. 1,2-Dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3- pyridinecarbonitrile (11a) hydrochloride monohydrate (E-1020) was found to be a potent and selective inhibitor of phosphodiesterase III and a long-acting, potent, orally active positive inotropic agent. Additional imidazo[1,2-a]pyridin-2-yl (3a), -3-yl (16), -7-yl (20) and -8-yl (24a) compounds were also prepared. Altering the pyridine substitution from the 2-position to the 6-position produced a 2-fold increase in the i.v. cardiotonic potency (ED50) from 52 to 23 μg/kg, while substitution at the 3-, 7- or 8-position reduced potency. In the 2-positional isomers, introduction of halogen groups enhanced the activity and 3-chloro-1,2-dihydro-5-(6-fluoroimidazo[1,2-a]pyridin-2-yl)-6-methyl-2(1H)- pyridinone (3a) was the most potent (i.v. ED50 11 μg/kg) in this seris. E-1020 is presently under development for the treatment of congestive heart failure.